Form 6-K OKYO Pharma Ltd For: May 18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

May 2022

 

 

Commission File Number: 001-41386

 

 

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

 

 

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On May 18, 2022, OKYO Pharma LTD (the “Company”) issued a news service announcement in the United States announcing a PDMR dealing.

 

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	OKYO Pharma LTD
Date: May 18, 2022	By:	/s/ Gary Jacob
	Name:	Gary Jacob
	Title:	Chief Executive Officer

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		News Service Announcement, dated May 18, 2022

 

 

 

Exhibit 99.1

 

PDMR Dealing

 

London and New York, NY, 18 May, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 25,000 ADSs (each representing 65 ordinary shares of no par value in the market) at a price of US$3.8749 per ADS.

 

The acquisition increase Mr Cerrone’s beneficial interests in the capital of the Company from 39.52% to 39.64% (however the impact of the announced offering closing on 19 May 2022 (the “Offering”) will reduce this holding to, in aggregate, 38.50% after allowing for; (i) the ordinary shares to be issued in the Offering; and (ii) the 25,000 ADS purchased by Mr Cerrone in the Offering).

 

1.	Details of PDMR / person closely associated
a)	Name		Gabriele Cerrone
2.	Reason for the notification
a)	Position / status		Chairman
b)	Initial notification /amendment		Initial notification
3.	Details of the issuer
a)	Name		OKYO Pharma Limited
b)	LEI		213800VVN5CB56Y15A05
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument		ADS representing 65 Ordinary Shares of no par value
b)	Identification code of the Financial Instrument		ISIN for OKYO Pharma Limited ADS: US6793451088
c)	Nature of the transaction		Market Purchase
d)	Price(s) and volume(s)		US$3.8749 - 25,000
f)	Date of the transaction		17 May 2022
g)	Place of the transaction		NASDAQ

 

 

Enquiries:

 

OKYO Pharma Limited		Gary S. Jacob, Chief Executive Officer   Gabriele Cerrone, Non-Executive Chairman		+44 (0)20 7495 2379
Optiva Securities Limited (Broker)		Robert Emmet		+44 (0)20 3981 4173
RedChip Companies Inc. (Investor Relations)		Dave Gentry		[email protected]   +1 407-491-4498

 

Notes for Editors:

 

About OKYO

 

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

 

About OK-101

 

OK-101 is a lipidated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immunological cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) Technology to produce a novel long-acting drug candidate for treating DED. OK-101 has been shown to produce anti-inflammatory activity in mouse models of DED and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

 

About Dry Eye Disease (DED)

 

Dry eye is a multifactorial disease that results in ocular discomfort and tear film instability that can lead to ocular surface damage. It is often a chronic problem, particularly in older adults, and is expected to become even more prevalent with the aging population and increased use of digital screens such as computers and smart phones. Despite new product approvals, dry eye disease (DED) remains a significant unmet medical need and is one of the leading causes for patient visits to eye care specialists. Novel therapies that improve the signs and symptoms of dry eye disease will be beneficial to dry eye patients.

 

For further information, please visit the Company’s website at www.okyopharma.com.

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nature’s Answer Introduces Maca Root Extract to Its Range of Bio-Chelated Extracts
• Sustainable Infrastructure Dividend ETF Distributions
• PDP Celebrates Fortnite Festival Season 3 With the Launch of the RIFFMASTER Wireless Guitar Controller